Now more than ever, pork producers are looking for new and innovative ways to help support the care and wellbeing of their animals. The continuous threat of animal disease, social and regulatory pressure to reduce antibiotic use, along with increasing consumer interest in on-farm production practices has them looking more and more to prevention-based solutions. Merck Animal Health understands this challenge and has responded by making investments in swine vaccine advancements and new manufacturing facilities, as well as building a team of industry and veterinary experts.
Disease outbreaks have significantly impacted all aspects of production agriculture: bovine spongiform encephalopathy (BSE) in cattle, avian influenza in poultry and porcine epidemic diarrhea (PED) in swine, just to name a few. Recognizing the need for greater preventive strategies across the industry, Merck Animal Health acquired an innovator in animal vaccine technology – Harrisvaccines – to add value to its already robust portfolio of vaccines.
The unique RNA Particle technology represents a breakthrough in vaccine development with a highly versatile production platform able to target a wide range of viruses and bacteria. Pathogens are collected from a farm and specific genes are sequenced and inserted into the platform, making safe, potent vaccines that provide herd-specific protection. For the full article click here
from health IT caucus http://ift.tt/2g6vvcS
via IFTTT
No comments:
Post a Comment